Shares of Moderna rose 3.63% to $142.00 at 11:56 EST on Thursday, after three successive sessions in a row of losses. The Nasdaq Stock Market is rising 0.54% to $12,727.00, after three consecutive sessions in a row of gains. This seems, up until now, a somewhat positive trend trading session today.

Moderna’s last close was $137.03, 25.70% below its 52-week high of $178.50.

News about Moderna today

FDA panel expected to back Moderna Covid-19 vaccine. According to today’s article on The Wall Street Journal, "A federal vaccine-advisory committee is likely to recommend that the Food and Drug Administration grant an emergency-use authorization for the new Covid-19 vaccine from Moderna Inc. when the panel meets Thursday, its chairman said."

Global market outlook for the coronavirus vaccine market to 2027, featuring Moderna inc, geovax, inovio pharmaceuticals and more. According to today’s article on Business Insider, "Some of the key players profiled in the Coronavirus Vaccine Market include Inovio Pharmaceuticals, Inc., Moderna, Inc., Protein Potential, LLC, Novavax, Inc., Synairgen PLC, AlphaVax, Inc., NanoViricides, Inc., Zydus Cadila, Bravovax, GeoVax, Altimmune, Janssen Pharmaceutical Companies, CanSino Biologics, Vaxart and Vaxil Bio Ltd.", "Key Topics Covered:1 Executive Summary 2 Preface3 Market Trend Analysis4 Porters Five Force Analysis5 Global Coronavirus Vaccine Market, By Infection Type6 Global Coronavirus Vaccine Market, By Vaccine Type7 Global Coronavirus Vaccine Market, By Product Type8 Global Coronavirus Vaccine Market, By Route of Administration9 Global Coronavirus Vaccine Market, By Patient Type10 Global Coronavirus Vaccine Market, By End User11 Global Coronavirus Vaccine Market, By Geography12 Key Developments13 Company Profiling13.1 Inovio Pharmaceuticals, Inc. 13.2 Moderna, Inc. 13.3 Protein Potential, LLC 13.4 Novavax, Inc. 13.5 Synairgen PLC 13.6 AlphaVax, Inc. 13.7 NanoViricides, Inc. 13.8 Zydus Cadila 13.9 Bravovax 13.10 GeoVax 13.11 Altimmune 13.12 Janssen Pharmaceutical Companies 13.13 CanSino Biologics 13.14 Vaxart 13.15 Vaxil Bio Ltd For more information about this report visit https://www.researchandmarkets.com/r/5b6t0s"

Moderna’s Sales

Moderna’s sales growth is 1665.3% for the present quarter and 15587.1% for the next. The company’s growth estimates for the ongoing quarter is a negative 29.7% and positive 685.7% for the next.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $142.00 at 11:56 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna’s Moving Average

Moderna’s value is way higher than its 50-day moving average of $110.24 and way above its 200-day moving average of $79.01.

Previous days news about Moderna

Take-two, occidental petroleum, Moderna: what to watch when the stock market opens today. According to The Wall Street Journal on Tue Dec 15, "-Shares of the vaccine maker Moderna were down 1% premarket. "

Moderna vaccine found safe, effective ahead of key FDA review. According to Bloomberg Quint on Tue Dec 15, "Between Pfizer and Moderna, Operation Warp Speed officials have said 20 million people in the U.S. are expected to get their first shots by year-end.", "The shot must be kept extremely cold and requires special freezers to transport, while Moderna’s can be kept in more traditional cold storage."

Moderna vaccine found safe, effective before key FDA review. According to Bloomberg Quint on Tue Dec 15, "The FDA staff’s analysis of Moderna’s trial data found 11 cases of Covid-19 in the group that received the vaccine and 185 in those that got a placebo instead.", "Moderna’s vaccine will be distributed to sites around the country where health-care workers and residents of long-term care facilities, such as nursing homes, are expected to get the earliest doses."

Moderna shares up in premarket as FDA calls Covid-19 vaccine 'highly effective'. According to MarketWatch on Tue Dec 15, "Shares of Moderna Inc. gained 1.5% in premarket trading on Tuesday after the Food and Drug Administration said the company’s COVID-19 vaccine candidate is “highly effective” at preventing infections with the coronavirus. "

Canada to receive early access to Moderna Covid-19 vaccine. According to Business Insider on Tue Dec 15, "The logistical planning for the delivery of Moderna doses is complete, and shipments to Canada could begin within 48 hours of regulatory approval.", "As with all COVID-19 vaccine candidates, the Moderna vaccine must be authorized by Health Canada before being administered to Canadians."

Moderna to offer covid shots to volunteers who got placebo. According to Bloomberg Quint on Tue Dec 15, "Moderna Inc. is preparing to offer its Covid-19 shot to trial participants who received a placebo in the final-stage study once the vaccine is authorized for emergency use in the U.S.", "Ray Jordan, a Moderna spokesman, confirmed the letter was being prepared."

Stocks making the biggest moves in the premarket: tilray, Aphria, penumbra, Moderna & more. According to CNBC on Wed Dec 16, "Moderna (MRNA) – Moderna was downgraded to "hold" from "buy" at Jefferies, which cited the significant runup in the drugmaker’s stock as well as high expectations surrounding its Covid-19 vaccine. "

Moderna party ending, analysts caution before shot approval. According to Bloomberg Quint on Wed Dec 16, "Moderna’s valuation may be at risk if retail interest wanes as new vaccines become a reality. ", "Moderna now has nine buys, seven holds and two sell ratings, according to data compiled by Bloomberg."

LEAVE A REPLY

Please enter your comment!
Please enter your name here